Tazzle, which contains the active ingredient Tadalafil, belongs to a class of medications known as phosphodiesterase type 5 (PDE5) inhibitors. It primarily affects blood flow in the body by targeting a specific enzyme called phosphodiesterase type 5 (PDE5).
When a man experiences sexual arousal, the body releases a chemical called nitric oxide (NO) in the erectile tissue of the penis. Nitric oxide activates an enzyme called guanylate cyclase, which, in turn, increases the production of cyclic guanosine monophosphate (cGMP). cGMP is a crucial chemical messenger that relaxes the smooth muscles in the penile arteries and allows them to dilate (widen).
In normal circumstances, after sexual activity is complete, another enzyme called PDE5 breaks down cGMP, which reverses the dilation of the penile arteries and brings the penis back to its flaccid state.
However, in men with Erectile Dysfunction (ED), this process is disrupted. PDE5 may be overly active, leading to a faster breakdown of cGMP and inadequate blood flow to the penis, resulting in difficulty achieving and maintaining an erection.
This is where Tazzle, with its active ingredient Tadalafil, comes into play. Tadalafil is a PDE5 inhibitor, meaning it inhibits the action of the PDE5 enzyme. By doing so, Tadalafil helps to maintain higher levels of cGMP in the penile arteries for a more extended period.